An informa business SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President...
-
Upload
grace-quinlan -
Category
Documents
-
view
219 -
download
5
Transcript of An informa business SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President...
![Page 1: An informa business SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.](https://reader035.fdocuments.us/reader035/viewer/2022062511/5514eff155034693478b5e1f/html5/thumbnails/1.jpg)
An informa business www.citeline.com
SLA Pipeline Town Hall Meeting
Christine Blazynski PhDSr. Vice-President
Product Development
![Page 2: An informa business SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.](https://reader035.fdocuments.us/reader035/viewer/2022062511/5514eff155034693478b5e1f/html5/thumbnails/2.jpg)
An informa business www.citeline.com
TrialTroveClinical Trials Intelligence
Integrated and Enterprise-Wide ServicesPipeline / Pharmaprojects
Drug Intelligence
All Drugs InDevelopmentFrom BenchTo Market
TrialPredictTrials Timing / Benchmarking
Citeline Proprietary
Prediction of Trials Enrollment
Timing
World’s foremost collection
of
clinical trials,investigators, sites,
drugs & analysis
Global Coverage
Of Clinical Trials Design and Status
SiteTroveInvestigator / Site Selection
Investigators And Sites
Based UponDirect TrialsExperience
Citeline AnalyticsMapping the Competition
Map Date:
6/23/07 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Adjuvant
Phase II Biomarker/Tox
Phase III Biomarker/SE, PGX
EI, Biomarker/SE, PGX
Neoadjuvant
Phase II Biomarker/SE
PGX
Biomarker/SE
Biomarker/SE
Biomarker/SE
PGX
Biomarker/SE
Biomarker/SE
Phase III Biomarker/SE, PGX
PGX
NeoAdjuvant and Adjuvant
Phase II Biomarker/Tox
2010 2011
Competitive Development Map
20142012 201320052004
Drug: Tykerb (Lapatinib)Disease: Breast CancerAdjuvant and Neoadjuvant Therapy
2006 2007 2008 2009
Lap +Tras (+ AC,Doxo,Pac,Surg), 0/I/II/III, TA100, #70768
Lap, I/II/III, TA150, #52438
Lap, I/II/III, TA120, #45628
Lap (+ AC,Doc,Doxo), II/III, TA71, #60281
Lap (+/vs Tras, + Chemo), II/III, TA120, #63895
Lap (+/vs Tras, + Pac), I/II, TA450, NEO-ALTTO, (#53035)
Lap (+/vs Tras, +AC,Doxo), II/III, TA522, #71240
Lap (+/vs Let), II/III, TA91, #63171
Lap, II/III, #51923
Lap, II/III/IV, TA22-55, #33321
Lap (+ AC,Doxo,Pac,Tras), 0/I/II/III, TA109, #65110
Lap (4-arm trial), I/II, TA8000, ALTTO, (#45399)
Lap, I/II/III, TA3000, TEACH, (#56312)
Lap (+/vs Tras, + AC,Doxo), I/II, #55823
Lap (+ Pac,Surg), III/IV, AA50/TA60, #29064
Lap (+ Ab), I/II/III, TA30, #50405
Visualization ofClinical
DevelopmentPrograms
![Page 3: An informa business SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.](https://reader035.fdocuments.us/reader035/viewer/2022062511/5514eff155034693478b5e1f/html5/thumbnails/3.jpg)
An informa business www.citeline.com
Depth and Breadth of Citeline Data
150 countries covered 180+ disease areas in TrialTrove/ >1000 in Pipeline
☐ 222 therapeutic categories in Pipeline 250+ analysts and editors 18,000 data sources >4,000 companies developing therapeutics >46,000 drugs
☐ Over 30 years of history >120,000 interventional trials >250,000 investigator profiles
![Page 4: An informa business SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.](https://reader035.fdocuments.us/reader035/viewer/2022062511/5514eff155034693478b5e1f/html5/thumbnails/4.jpg)
An informa business www.citeline.com
Citeline’s Drug Intelligence
One centralized database of drug information
Deep integration with Citeline’s clinical development offerings
![Page 5: An informa business SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.](https://reader035.fdocuments.us/reader035/viewer/2022062511/5514eff155034693478b5e1f/html5/thumbnails/5.jpg)
An informa business www.citeline.com
Pharmaprojects
Legacy pipeline database☐ PJB publications
Thirty-one continual years of tracking drug development☐ Print 3rd party electronic distributer CD ROM Web
delivery☐ Updated once weekly
Trends data from 1995 through 2010
![Page 6: An informa business SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.](https://reader035.fdocuments.us/reader035/viewer/2022062511/5514eff155034693478b5e1f/html5/thumbnails/6.jpg)
An informa business www.citeline.com
Pipeline
Continually updated/real-time
Clean, simple, user-friendly interface
Customized alerts, saved searches, and share search
Unlimited research support
Search criteria expanded over time
All fields export or disease-focused export
Integration with TrialTrove, SiteTrove and TrialPredict
![Page 7: An informa business SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.](https://reader035.fdocuments.us/reader035/viewer/2022062511/5514eff155034693478b5e1f/html5/thumbnails/7.jpg)
An informa business www.citeline.com
Export Options
![Page 8: An informa business SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.](https://reader035.fdocuments.us/reader035/viewer/2022062511/5514eff155034693478b5e1f/html5/thumbnails/8.jpg)
An informa business www.citeline.com
![Page 9: An informa business SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.](https://reader035.fdocuments.us/reader035/viewer/2022062511/5514eff155034693478b5e1f/html5/thumbnails/9.jpg)
An informa business www.citeline.com
Recent Enhancements
☐ Hierarchical mechanism search
☐ Addition of biosimilars/biogenerics
☐ Company country HQ search and research focus
☐ Delivery route/medium/technology search
☐ Advanced search [phase 1]
☐ Automatic search for trials from multiple drug results
☐ Search by latest change date or range
![Page 10: An informa business SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.](https://reader035.fdocuments.us/reader035/viewer/2022062511/5514eff155034693478b5e1f/html5/thumbnails/10.jpg)
An informa business www.citeline.com
Pipeline
![Page 11: An informa business SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.](https://reader035.fdocuments.us/reader035/viewer/2022062511/5514eff155034693478b5e1f/html5/thumbnails/11.jpg)
An informa business www.citeline.com
Planned Enhancements
☐ Advanced Search: nested booleans, ability to move search terms, edit operators within and between categories
☐ NCE search
☐ Search by chemical name
☐ Search by originator OR licensee
☐ Trial reporting: tabular view
☐ Dashboard reporting
![Page 12: An informa business SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.](https://reader035.fdocuments.us/reader035/viewer/2022062511/5514eff155034693478b5e1f/html5/thumbnails/12.jpg)
An informa business www.citeline.com
![Page 13: An informa business SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.](https://reader035.fdocuments.us/reader035/viewer/2022062511/5514eff155034693478b5e1f/html5/thumbnails/13.jpg)
An informa business www.citeline.com
Citeline’s Drug Intelligence
One centralized database of drug information
Drug, company data to meet all business development needs
![Page 14: An informa business SLA Pipeline Town Hall Meeting Christine Blazynski PhD Sr. Vice-President Product Development.](https://reader035.fdocuments.us/reader035/viewer/2022062511/5514eff155034693478b5e1f/html5/thumbnails/14.jpg)
An informa business www.citeline.com
Citeline - MedTrack MedTrack joined Citeline in late March 2011. As of April 6:
☐ 21,326 companies☐ 107,199 drugs (not all unique; includes generics)☐ 1,556 drug delivery technologies☐ 55,758 deals☐ 642 indications☐ 615,114 searchable news releases☐ 142,525 management bios☐ 481,558 searchable SEC documents
MedTrack V2 migration continues Planning for initial integration between products just starting but clear
synergies exist Need for market research and focus groups……… will you help?